Skip to main navigation
Skip to search
Skip to main content
Sort by
Immunology and Microbiology
Rhesus Monkey
85%
Simian Immunodeficiency Virus
57%
Viral Disease
45%
Zika Virus
34%
Infection
28%
Infectious Disease
27%
Human Immunodeficiency Virus
26%
Macaca
25%
Virus
21%
Allogeneic Stem Cell Transplantation
20%
Viral Load
20%
Allogeneic Hematopoietic Stem Cell Transplantation
19%
Blood Plasma
19%
Macaca fascicularis
17%
Infectious Agent
16%
Ribonucleic Acid
15%
Rebound
14%
Immunopathology
13%
Inflammation
13%
Replication
13%
T-Helper Cell
12%
Hematopoietic Stem Cell Transplantation
12%
Immune System
10%
Lymphoid Tissue
10%
Gastrointestinal Tract
8%
Histone
8%
Viral Replication
7%
Lymph Node
7%
Cytotoxic T-Cell
7%
Xenotropic MuLV Related Virus
6%
Pharmacokinetics
6%
Tumor Necrosis Factor
6%
Opportunistic Infection
6%
Gammaherpesvirus
6%
Immunogenicity
6%
Interleukin 15
6%
2,5-Dimethoxy-4-iodoamphetamine
6%
Alemtuzumab
6%
Lymphocyte
6%
Macaca nemestrina
6%
Cerebrospinal Fluid
6%
Lymphocryptovirus
6%
DNA Virus
6%
Adalimumab
5%
Viremia
5%
Inflammation Response
5%
CCR5
5%
Viral Clearance
5%
Viral Reservoir
5%
Tenofovir
5%
Keyphrases
Rhesus Macaque
100%
Zika Virus Infection
34%
Macaque
29%
Macaca mulatta
22%
Inflammation
20%
Simian Immunodeficiency Virus
18%
SIVmac239
17%
Nonhuman Primate
16%
Zika Virus
15%
Multiple Tissues
13%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
13%
Viral Persistence
13%
Infectious Diseases
13%
Cynomolgus Macaque
13%
Immunopathology
13%
Combined Antiretroviral Therapy (cART)
13%
Combined Modality Therapy
13%
Treatment Regimen
13%
Probability of Line of Sight (PLoS)
13%
Gastrointestinal Tract
13%
Lymphoid Tissue
11%
Nonhuman Primate Model
10%
Immune System
10%
Viral
10%
Behavior Management
9%
Uterus
9%
CD4+ T
8%
Miscarriage
8%
Clinical Outcomes
8%
Hematopoietic Stem Cell Transplantation
8%
Residual Virus
8%
Congenital Zika Syndrome
8%
Ki-67
8%
Antiretroviral Therapy Regimens
7%
Human Trials
7%
Antiretroviral Therapy
7%
Stillbirth
6%
Pairing Success
6%
Immunogenicity
6%
Transplant Infectious Diseases
6%
Recombinant Human
6%
Port System
6%
Safety Toxicity
6%
Interleukin-15 (IL-15)
6%
Safety Impact
6%
Alemtuzumab
6%
Clinical Management
6%
Lymphocyte Depletion
6%
Cardiomyopathy
6%
Antiretroviral Therapy Interruption
6%